MAY – JUNE 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA June 6 – Durvalumab – NSCLC EGFR/ALK. The European Commission (EC) has approved a Type II variation extension of indication to include the anti-PD-L1 antibody in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, for the treatment of adults with resectable (tumours ? 4 cm and/or node positive) non-small […]